Table 1.
SGK3 IHC staining in association with clinicopathologic features. %* indicates the percentage of patients out of each corresponding subgroup from the preceding column.
| Clinicopathologic features | Number of patients (%) (Total=133) |
Number of positive SGK3 staining (%*) |
P-value (Fisher’s exact test) |
|---|---|---|---|
| Patient age | 1.00 | ||
| ≤ 55 yrs | 68 (51%) | 36 (53%) | |
| > 55 yrs | 65 (49%) | 35 (54%) | |
| Tumor type | 0.83 | ||
| IDC/IMC | 118 (89%) | 62 (53%) | |
| ILC | 11 (8%) | 7 (63%) | |
| Metaplastic carcinoma | 4 (3%) | 2 (50%) | |
| Tumor size | 0.31 | ||
| ≤2 cm | 75 (56%) | 37 (49%) | |
| >2 cm and ≤ 5 cm | 41 (31%) | 26 (63%) | |
| >5 cm | 17 (13%) | 8 (47%) | |
| Tumor Grade | 0.008 | ||
| 1 | 16 (12%) | 12 (75%) | |
| 2 | 58 (44%) | 36 (62%) | |
| 3 | 59 (44%) | 23 (39%) | |
| Axillary lymph node status | 0.02 | ||
| Negative | 70 (53%) | 36 (51%) | |
| Micrometastasis | 2 (2%) | 1 (50%) | |
| 1–3 positive | 36 (27%) | 14 (39%) | |
| 4–9 positive | 16 (12%) | 13 (81%) | |
| >10 positive | 9 (7%) | 7 (78%) | |
| Neoadjuvant chemotherapy | 0.16 | ||
| Yes | 34 (26%) | 22 (65%) | |
| No | 99 (74%) | 49 (50%) | |
| ER status | <0.0001 | ||
| Positive (≥1%) | 80 (60%) | 56 (70%) | |
| Negative | 52 (39%) | 14 (27%) | |
| Unknown | 1 (1%) | 1 (100%) | |
| PR status | <0.0001 | ||
| Positive (≥1%) | 74 (56%) | 51 (69%) | |
| Negative | 58 (44%) | 19 (33%) | |
| Unknown | 1 (1%) | 1 (100%) | |
| HER2 status | 0.68 | ||
| Positive | 6 (5%) | 4 (67%) | |
| Negative | 126 (95%) | 66 (52%) | |
| Unknown | 1 (1%) | 1 (100%) | |
| Ki67 status | 0.09 | ||
| Low (≤17%) | 21 (16%) | 15 (71%) | |
| Intermediate (>17% and ≤ 35%) | 12 (9%) | 7 (58%) | |
| High (>35%) | 19 (14%) | 7 (37%) | |
| Unknown | 81 (61%) | 42 (52%) | |
| Triple-negative status | <0.0001 | ||
| Yes | 47 (36%) | 12 (26%) | |
| No | 85 (64%) | 58 (68%) | |
| Unknown | 1 (1%) | 1 (100%) | |